Læknaneminn

Ataaseq assigiiaat ilaat

Læknaneminn - 01.04.1997, Qupperneq 117

Læknaneminn - 01.04.1997, Qupperneq 117
The drug-AIDS hypothesis * ued after a short traumatic, but reversible experience. Independent scientists document that in addition to abstaining from antiviral drugs long-term survivors are those who have given up or never taken recreational drugs 253'255. Timothy Hand, from the Ogelthorpe University in Atlanta GA, adds rnuch weight to this view: While healthy, ‘non-progressing’ HIV carriers are considered rare (and doomed), they may in fact vastly outnumber the sick and dying. This is certainly implied by the ubiquitous estimate of HIV prevalence in America of one million. Long-term AIDS survival is now a hot topic in the literature, and anecdotal reports 256’257 as well as numerous scientific studies 101, 25i, 258-264 suggest that most long-term survivors have shunned antiviral drugs. This point is often understat- ed in these studies, and is not made in the titles or abstracts. In David Baltimore’s editorial on 2 of these studies, avoidance of antivirals was not mentioned at all 265. Needless to say, none of these studies was fund- ed by a pharmaceutical firm. Interestingly, nearly all of these studies suggest a pro- tective role of cytotoxic CD8+ T-cells and/or natural killer cells in healthy survivors. Many focus on the importance of maintaining cell-mediated immunity, rather than on “killing HIV”. Thus HIV infection per se seems to entail little danger, unless it is followed by antiviral therapy. 266. Similar observations have been made by the late homosexual AIDS activist Michael Callen: [I]n researching his 1990 book Surviving AIDS, Callen interviewed nearly fifty people who had lived for many years not just after being pronounced HIV- positive, but after an AIDS diagnosis. He found that only four had ever used AZT; three of those had since died, and one was dying of AZT-induced lymphoma. But the overwhelming majority of long-term survivors had somehow managed to resist the enormous pressure to take AZT. The pressure did not just come from doctors, Callen told the Amsterdam meeting 7'267, but from a certain segment of AIDS activism that seemed driven by a ‘drugs-into-bodies’ mentality. ‘I feel many AIDS activist friends who are in the forefront of this frenzy are very misleading to people with AIDS, who are frightened and desperate. They only seem to talk about two possible outcomes of taking experimental drugs: one is that it works and one that it does not worlc. There is a third, apparently much more com- mon possibility, which is that you will be worse off than if you did nothing at all. And nobody likes to talk about that because it is so unpleasant’. He had seen the devastation wreaked by AZT, watching with horror as friends with AIDS ‘turn the colour of boiled ham from AZT poisoning, endure the melting away of their mus- cles, become transfusion dependent, and experience drug-induced psychosis’. Yet his perception of a person diagnosed with AIDS in 1992 was that ‘they would sell their grandmother into slavery to get a slot in the latest drug-of-the-month clinical trial’. Another feature of the long-term survivors was that they rejected the predominant scientific view that HlV-positivity meant inevitable decline of the immune system towards an early death 1. In December 1995 The Advocate, the largest nation- al gay magazine, published the story of Dennis Leoutsakas, a man who is HlV-positive “for at least 17 years [but] doesn’t have AIDS — and no one knows why” 268. According to the article, “most HIV researchers have insisted that HIV infection will, in almost every case, eventually lead to AIDS” — a belief underscored by their preferred term for nonprogres- sors: slow progressors. Wearing his HIV blinkers the author of the article fails to see the formula for Leoutsakas’ “slow progres- sion”: “ Leoutsakas, 47: A former IV-drug user who last shared a needle in 1978 ... first tested positive in 1987. He has aT-cell count ... between 650 and 950. In addition, Leoutsakas has had none of the oppor- tunistic infections that define AIDS - no pneumonia, no Kaposi’s sarcoma, no fungal infections, nada. Leoutsakas says doctors have attempted to explain his case by theorizing that, like the Australians 249, he is infected with a weakened form of HIV - but it’s really just speculation.” ... “Leoutsakas has no theory of his own - and no special formula for his well-being. He’s never taken AZT or any other antiretroviral drugs.” No more IV-drugs, no antiretroviral drugs — but “no formula for his well-being”! And in October 1996 even an orthodox professor of medicine at the University of California at San Francisco taught his medical students the secret of long-term survival with HIV (see 4.): “I have a Iarge population of people who have chosen not to take any LÆKNANEMINN 115 1. tbl. 1997, 50. árg.
Qupperneq 1
Qupperneq 2
Qupperneq 3
Qupperneq 4
Qupperneq 5
Qupperneq 6
Qupperneq 7
Qupperneq 8
Qupperneq 9
Qupperneq 10
Qupperneq 11
Qupperneq 12
Qupperneq 13
Qupperneq 14
Qupperneq 15
Qupperneq 16
Qupperneq 17
Qupperneq 18
Qupperneq 19
Qupperneq 20
Qupperneq 21
Qupperneq 22
Qupperneq 23
Qupperneq 24
Qupperneq 25
Qupperneq 26
Qupperneq 27
Qupperneq 28
Qupperneq 29
Qupperneq 30
Qupperneq 31
Qupperneq 32
Qupperneq 33
Qupperneq 34
Qupperneq 35
Qupperneq 36
Qupperneq 37
Qupperneq 38
Qupperneq 39
Qupperneq 40
Qupperneq 41
Qupperneq 42
Qupperneq 43
Qupperneq 44
Qupperneq 45
Qupperneq 46
Qupperneq 47
Qupperneq 48
Qupperneq 49
Qupperneq 50
Qupperneq 51
Qupperneq 52
Qupperneq 53
Qupperneq 54
Qupperneq 55
Qupperneq 56
Qupperneq 57
Qupperneq 58
Qupperneq 59
Qupperneq 60
Qupperneq 61
Qupperneq 62
Qupperneq 63
Qupperneq 64
Qupperneq 65
Qupperneq 66
Qupperneq 67
Qupperneq 68
Qupperneq 69
Qupperneq 70
Qupperneq 71
Qupperneq 72
Qupperneq 73
Qupperneq 74
Qupperneq 75
Qupperneq 76
Qupperneq 77
Qupperneq 78
Qupperneq 79
Qupperneq 80
Qupperneq 81
Qupperneq 82
Qupperneq 83
Qupperneq 84
Qupperneq 85
Qupperneq 86
Qupperneq 87
Qupperneq 88
Qupperneq 89
Qupperneq 90
Qupperneq 91
Qupperneq 92
Qupperneq 93
Qupperneq 94
Qupperneq 95
Qupperneq 96
Qupperneq 97
Qupperneq 98
Qupperneq 99
Qupperneq 100
Qupperneq 101
Qupperneq 102
Qupperneq 103
Qupperneq 104
Qupperneq 105
Qupperneq 106
Qupperneq 107
Qupperneq 108
Qupperneq 109
Qupperneq 110
Qupperneq 111
Qupperneq 112
Qupperneq 113
Qupperneq 114
Qupperneq 115
Qupperneq 116
Qupperneq 117
Qupperneq 118
Qupperneq 119
Qupperneq 120
Qupperneq 121
Qupperneq 122
Qupperneq 123
Qupperneq 124
Qupperneq 125
Qupperneq 126
Qupperneq 127
Qupperneq 128
Qupperneq 129
Qupperneq 130
Qupperneq 131
Qupperneq 132
Qupperneq 133
Qupperneq 134
Qupperneq 135
Qupperneq 136
Qupperneq 137
Qupperneq 138
Qupperneq 139
Qupperneq 140

x

Læknaneminn

Direct Links

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknaneminn
https://timarit.is/publication/1885

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.